The management of gastrointestinal stromal tumors: A model for targeted and multidisciplinary therapy of malignancy

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 247-258

  Joensuu, Heikki ^a   Dematteo, Ronald P ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Cancer; Imatinib; Sarcoma; Sunitinib; Tyrosine kinase

Indexed keywords

GLYCOPROTEIN P; IMATINIB; MASITINIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SORAFENIB; SUNITINIB; VATALANIB;

ADJUVANT THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEMOGLOBIN DETERMINATION; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; RISK ASSESSMENT; STOMACH PAIN; SYNCOPE; TUMOR BLEEDING;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PYRIMIDINES; RISK FACTORS;

EID: 84855927262     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-043010-091813     Document Type: Review

References (54)

1. Mazur MT, Clark HB. 1983. Gastric stromal tumors. Reappraisal of histogenesis. Am. J. Surg. Pathol. 7:507-19 (Pubitemid 13021488)
2. Miettinen M. 1988. Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiation. Am. J. Clin. Pathol. 89:601-10
3. Hirota S, Isozaki K, Moriyama Y, et al. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-80 (Pubitemid 28067289)
4. Broudy VC. 1997. Stem cell factor and hematopoiesis. Blood 90:1345-64 (Pubitemid 27355406)
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. 2001. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:1052-56 (Pubitemid 32267975)
6. Demetri GD, vonMehren M, Blanke CD, et al. 2002. Efficacy and safety of imatinibmesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:472-80 (Pubitemid 34879334)
7. Joensuu H, Fletcher C, Dimitrijevic S, et al. 2002. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3:655-64 (Pubitemid 35314908)
8. Mucciarini C, Rossi G, Bertolini F, et al. 2007. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 7:230
9. Nilsson B, Bumming P, Meis-Kindblom JM, et al. 2005. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinibmesylate era-a population-based study in western Sweden. Cancer 103:821-29 (Pubitemid 40216412)
10. Steigen SE, Eide TJ. 2006. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS 114:192-200
11. Heinrich MC, Corless CL, Duensing A, et al. 2003. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-10 (Pubitemid 36159485)
12. Pietras K, Sjoblom T, Rubin K, et al. 2003. PDGF receptors as cancer drug targets. Cancer Cell 3:439-43 (Pubitemid 38340290)
13. Martin J, Poveda A, Llombart-Bosch A, et al. 2005. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J. Clin. Oncol. 23:6190-98
14. DeMatteo RP, Gold JS, Saran L, et al. 2008. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608-15 (Pubitemid 351186201)
15. Kawanowa K, Sakuma Y, Sakurai S, et al. 2006. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum. Pathol. 37:1527-35 (Pubitemid 44792229)
16. Agaimy A, Wunsch PH, Hofstaedter F, et al. 2007. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am. J. Surg. Pathol. 31:113-20 (Pubitemid 46036910)
17. Miettinen M, Wang ZF, Lasota J. 2009. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am. J. Surg. Pathol. 33:1401-8
18. Novelli M, Rossi S, Rodriguez-Justo M, et al. 2010. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 57:259-70
19. Fletcher CD, Berman JJ, Corless C, et al. 2002. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33:459-65 (Pubitemid 34747864)
20. Miettinen M, Lasota J. 2006. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 23:70-83 (Pubitemid 44692418)
21. Joensuu H. 2008. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 39:1411-19
22. Gold JS, Gonen M, Gutierrez A, et al. 2009. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumor: a retrospective analysis. Lancet Oncol. 10:1045-52
23. Ng EH, Pollock RE, Munsell MF, et al. 1992. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann. Surg. 215:68-77
24. Hohenberger P, Ronellenfitsch U, Oladeji O, et al. 2010. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br. J. Surg. 97:1854-59
25. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. 2002. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 33:466-77 (Pubitemid 34747865)
26. Eisenberg BL, Harris J, Blanke CD, et al. 2009. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary andmetastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J. Surg. Oncol. 99:42-47
27. Blanke CD, Demetri GD, von Mehren M, et al. 2008. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KI T. J. Clin. Oncol. 26:620-25 (Pubitemid 351264357)
28. Raut CP, Posner M, Desai J, et al. 2006. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. 24:2325-31 (Pubitemid 46630664)
29. DeMatteo RP, Maki RG, Singer S, et al. 2007. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann. Surg. 245:347-52 (Pubitemid 46673128)
30. Plaat BE, Hollema H, Molenaar WM, et al. 2000. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol. 18:3211-20
31. Blanke CD, Rankin C, Demetri GD, et al. 2008. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26:626-32 (Pubitemid 351264358)
32. Choi H, Charnsangavej C, Faria SC, et al. 2007. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25:1753-59 (Pubitemid 46797957)
33. Heinrich MC, Corless CL, Demetri GD, et al. 2003. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:4342-49 (Pubitemid 46621810)
34. Verweij J, Casali PG, Zalcberg J, et al. 2004. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-34 (Pubitemid 39296599)
35. Debiec-Rychter M, Sciot R, Le Cesne A, et al. 2006. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42:1093-103 (Pubitemid 44275331)
36. Janeway KA, Kim SY, Lodish M, et al. 2011. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl. Acad. Sci. USA 108:314-18
37. Pantaleo MA, Astolfi A, Indio V, et al. 2011. SDHA loss-of-function mutations in KIT-PDGFRA wildtype gastrointestinal stromal tumors identified by massively parallel sequencing. J. Natl. Cancer Inst. 103:983-87
38. Agaram NP, Wong GC, Guo T, et al. 2008. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853-59
39. Blay JY, Le Cesne A, Ray-Coquard I, et al. 2007. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J. Clin. Oncol. 25:1107-13 (Pubitemid 46596763)
40. Le Cesne A, Ray-Coquard I, Bui BN, et al. 2010. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 11:942-49
41. Demetri GD, Wang Y, Wehrle E, et al. 2009. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J. Clin. Oncol. 27:3141-47
42. Heinrich MC, Corless CL, Blanke CD, et al. 2006. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24:4764-74 (Pubitemid 46630941)
43. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. 2006. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res. 12:1743-49
44. Liegl B, Kepten I, Le C, et al. 2008. Heterogeneity of kinase inhibitor resistance mechanisms in GIS T. J. Pathol. 216:64-74
45. Bono P, Krause A, von Mehren M, et al. 2004. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 103:2929-35 (Pubitemid 38451662)
46. Demetri GD, van Oosterom AT, Garrett CR, et al. 2006. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-38 (Pubitemid 44528723)
47. Joensuu H, De Braud F, Coco P, et al. 2008. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann. Oncol. 19:173-77
48. Montemurro M, Schoffski P, Reichardt P, et al. 2009. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur. J. Cancer 45:2293-97
49. Le Cesne A, Blay JY, Bui BN, et al. 2010. Phase II study of oral masitinibmesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur. J. Cancer 46:1344-51
50. DeMatteo RP, Ballman KV, Antonescu CR, et al. 2009. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097-104
51. Corless C, Ballman KV, Antonescu CR, et al. 2010. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J. Clin. Oncol. 28:15s
52. Bardsley MR, Horvath VJ, Asuzu DT, et al. 2010. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 139:942-52
53. Heinrich MC. 2010. Imatinib treatment of metastatic GIST: don't stop (believing). Lancet Oncol 11:910-11
54. Mahon FX, Rea D, Guilhot J, et al. 2010. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11:1029-35